China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

Researchers report detailed structural and atomic information for glassy and liquid magnesium silicates, which are important ...

Space-grown crystals could lead to targeted cancer drugsResearchers used space-grown protein crystals to determine the ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies ...

Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.

The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

Since its inception, Akeso Biopharma has remained steadfast in its commitment to original innovation in drug development. Through a differentiated strategy and forward-thinking approach, the company ...

Clinical trials with BNT327/PM8002 and the PD-(L)1 x VEGF bispecific class of drugs have demonstrated encouraging clinical ..

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...